*Introduction* Although psychoactive substance use disorders (PSUD) belong to the domain of mental health, their management varies greatly among European countries. Furthermore, both the role of psychiatrists and trainees in the treatment of PSUD is not the same for each European country.

Aims Among the context of the European Federation of Psychiatric Trainees (EFPT), the PSUD Working Group has developed a survey that has been spread out between the 15th of august 2015 and 15th of October 2016, at the aim of gathering information about the training in PSUD in Europe, both from Child and Adolescent, and General Adult Psychiatric (CAP and GAP) trainees.

*Objectives* The survey investigated, at European level, the organisation of the PSUD training, trainees satisfaction, attitudes towards people who use psychoactive substances, management of pharmacologic and involvement in common clinical situations.

*Methods* A 70-items questionnaire regarding the aforementioned objectives was developed, and shared trough an online data-collecting system among European CAP and GAP trainees, with 40 trainees per country filling the survey in at least 25 countries. One national coordinator per country facilitated the delivering of the survey.

*Results* A total of 1250 surveys were filled from more than 25 European countries.

*Conclusions* Data from the survey will be promptly analysed.

The survey will be the first to explore European psychiatric trainees attitudes and practices about PSUD. Findings from this independent survey may serve in understanding the needs of trainees in the field of substance misuse psychiatry.

*Disclosure of interest* The authors have not supplied their declaration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2017.01.570

### EV0241

### Hepatic comorbidity in psychiatry. A case report

G. Pardo de Santayana<sup>1,\*</sup>, R. Landera<sup>1</sup>, M. Juncal<sup>1</sup>, O. Porta<sup>1</sup>, L. Sánchez<sup>1</sup>, M. Gómez<sup>2</sup>, N. Núñez<sup>2</sup>

<sup>1</sup> Hospital universitario Marques De Valdecilla, psychiatry, Santander, Spain

<sup>2</sup> Hospital universitario Alava-sede Santiago- Vitoria-gasteiz, psychiatry, Vitoria, Spain

\* Corresponding author.

*Introduction* Comorbidity between mental and physical illnesses is very common and their possible interactions must always be taken into account. Hepatic disorders in particular, can affect the blood levels of antipsychotic drugs altering their effects on patients. Therefore, it is very important to assess in each case which treatment might be the most beneficial for the patient to avoid iatrogenic complications.

*Aim* To review articles in Pub-Med and UpToDate about the possible iatrogenic complications that can arise using antipsychotic drugs in patients with hepatic disorders.

*Methods* We describe the case of a 52-year-old male with Schizophrenia who was diagnosed of HCV infection ten years ago, for which he rejected any kind of treatment due to delirious ideation. In the past he was treated with oral Paliperidone with good tolerance, which he discontinued because of pour insight and stopped attending Psychiatric consultation. In April 2016 the patient was hospitalised suspecting a hepatocellular carcinoma.

*Results* During hospitalization he began treatment with longacting injectable formulation of Paliperidone Palmitate that improved his insight. The patient agreed to perform the necessary tests to verify the suspected diagnosis, which was sadly confirmed. He achieved psychopathological stability, but unfortunately the patient died 6 months later because of his hepatocellular carcinoma. *Conclusions* Paliperidone is a good therapeutic option in patients with hepatic disorders because it is not metabolised by the liver. It also has a depot formulation that improves adherence in patients with low insight, reducing the danger of future psychotic decompensation and improving the long-term prognosis.

*Disclosure of interest* The authors have not supplied their declaration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2017.01.571

### EV0242

## Cases where pituitary tumor is presented first with psychiatric signs are very rare

Dr. Taulant Pengili<sup>\*</sup>, M.S.Dr. Anila Hashorva, Dr. Ina Prifti, Dr. Marsida Lici, Dr. Enida Balani

University Hospital Center Mother Theresa, Psychiatry, Tirana, Albania

\* Corresponding author.

ObjectiveTo describe a rare case of Acromegaly presenting aspsychotic disorder without neurological signs, in a 19 years old boy.MethodSingle case report.

Results We describe the case of a 19 years old boy, that was taller than his peers and had started to grow his hands. He suddenly presented with an acute psychotic episode. He presented with persecutory delusions, perceptual abnormalities, disorganization and marked fluctuation in his behavior, he showed marked emotional liability, fluctuations in orientation and psychotic symptoms in the form of grandiosity, persecutory delusions and delusional misidentifications. At times, he was seen talking to himself, although he denied hearing any voices. There was no impairment of consciousness. His mood was irritable. An urgent CT and subsequent MRI scan revealed a pituitary macro adenoma, extending into the cavernous sinus. The initial diagnosis of prolactinoma was revised to acromegaly. His symptoms responded to combination of olanzapine and valproic acid, followed by trans sphenoid resection of the adenoma.

*Conclusions* This case highlights the need for investigation, especially of neuroimaging, in atypical presentations of psychosis, which may be first manifestation of rare disorders like acromegaly. Despite a lack of information regarding the path physiology, this particular case emphasizes the importance of ruling out an organic cause for atypical presentation of psychosis.

*Disclosure of interest* The authors have not supplied their declaration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2017.01.572

### EV0243

# Comorbidity between obsessive-compulsive disorder and attention deficit/hyperactivity disorder

J. Perestrelo<sup>\*</sup>, A. Samico, G. Lapa Centro hospitalar Vila Nova Gaia/Espinho, psychiatry and mental health, Porto, Portugal

\* Corresponding author.

*Introduction* The comorbidity between obsessive-compulsive disorder (OCD) and attention deficit/hyperactivity disorder (ADHD) has been discussed for a couple of decades. Reported co-occurrence rates are highly inconsistent in the literature.

*Objective* To review phenomenological and theoretical issues concerning concomitant OCD-ADHD.

*Aims* Phenomenological and theoretical issues regarding OCD-ADHD comorbidity are reviewed.

*Results* Although numerous studies suggest an OCD-ADHD comorbidity, thus far etiological (i.e., genetic) background has